CM
CM Management Portfolio holdings
AUM
$110M
This Quarter Return
+40.86%
1 Year Return
+9.76%
3 Year Return
+99.54%
5 Year Return
–
10 Year Return
–
AUM
$103M
AUM Growth
+$103M
(+22%)
Cap. Flow
-$4.3M
Cap. Flow
% of AUM
-4.2%
Top 10 Holdings %
Top 10 Hldgs %
44.11%
Holding
78
New
16
Increased
26
Reduced
11
Closed
5
Top Buys
| 1 |
ARKO Corp
ARKO
|
$1.43M |
| 2 |
CVS Health
CVS
|
$1.38M |
| 3 |
Coherus Oncology, Inc. Common Stock
CHRS
|
$1.07M |
| 4 |
B
Barrick Mining Corporation
B
|
$847K |
| 5 |
Talos Energy
TALO
|
$832K |
Top Sells
| 1 |
Preformed Line Products
PLPC
|
$1.64M |
| 2 |
OneSpan
OSPN
|
$1.23M |
| 3 |
TAST
Carrols Restaurant Group, Inc.
TAST
|
$882K |
| 4 |
Cytokinetics
CYTK
|
$815K |
| 5 |
ARKO Corp Warrant
ARKOW
|
$597K |
Sector Composition
| 1 | Healthcare | 42% |
| 2 | Industrials | 9.41% |
| 3 | Energy | 9.38% |
| 4 | Financials | 8.51% |
| 5 | Consumer Discretionary | 7.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRTK
51
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $553K | 0.54% |
250,000
-200,000
| -44% | -$442K |
|
52
Evolus
EOLS
$477M
| $545K | 0.53% |
+75,000
| New | +$545K |
|
53
Curis
CRIS
$21.5M
| $457K | 0.45% |
550,000
| – | – |
|
54
PagerDuty
PD
$1.44B
| $450K | 0.44% |
+20,000
| New | +$450K |
|
55
Nektar Therapeutics
NKTR
$543M
| $431K | 0.42% |
750,000
+350,000
| +88% | +$201K |
|
|
KRON
56
DELISTED
Kronos Bio
KRON
| $430K | 0.42% |
250,000
+70,000
| +39% | +$120K |
|
57
Lantern Pharma
LTRN
$46.3M
| $423K | 0.41% |
75,000
+15,000
| +25% | +$84.6K |
|
58
Gain Therapeutics
GANX
$69M
| $403K | 0.39% |
90,000
| – | – |
|
59
Applied Therapeutics
APLT
$73.7M
| $384K | 0.37% |
+300,000
| New | +$384K |
|
|
BCEL
60
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $343K | 0.33% |
350,000
+75,000
| +27% | +$73.5K |
|
|
61
Cytokinetics
CYTK
$5.98B
| $326K | 0.32% |
10,000
-25,000
| -71% | -$815K |
|
62
Eledon Pharmaceuticals
ELDN
$155M
| $322K | 0.31% |
234,803
+3
| +0% | +$4 |
|
63
NeueHealth
NEUE
$60.6M
| $314K | 0.31% |
25,715
-474,285
| -95% | +$238K |
|
64
Organon & Co
OGN
$2.56B
| $312K | 0.3% |
+15,000
| New | +$312K |
|
65
Edesa Biotech
EDSA
$17.2M
| $304K | 0.3% |
375,000
+50,000
| +15% | +$40.5K |
|
66
Newell Brands
NWL
$2.64B
| $261K | 0.25% |
+30,000
| New | +$261K |
|
67
Smith Micro Software
SMSI
$15.2M
| $250K | 0.24% |
225,000
+65,000
| +41% | +$72.2K |
|
68
Coya Therapeutics
COYA
$112M
| $244K | 0.24% |
+60,000
| New | +$244K |
|
69
Cadence Bank
CADE
$6.97B
| $196K | 0.19% |
+10,000
| New | +$196K |
|
70
Assertio
ASRT
$78M
| $136K | 0.13% |
+25,000
| New | +$136K |
|
71
Femasys
FEMY
$12M
| $123K | 0.12% |
241,373
| – | – |
|
|
PVLA
72
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $91K | 0.09% |
+550,000
| New | +$91K |
|
|
NBSE
73
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $11K | 0.01% |
6,000
-114,000
| -95% | – |
|
74
Vornado Realty Trust
VNO
$7.55B
| – | – |
-20,000
| Closed | -$307K |
|
75
Plains GP Holdings
PAGP
$3.71B
| – | – |
-35,000
| Closed | -$459K |
|